Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia

Core Insights - Hemostemix Inc. is advancing ACP-01, an autologous stem cell therapy, for the treatment of vascular dementia, with Dr. William R. Shankle leading the Phase I clinical trial [1][8][10] Company Overview - Hemostemix Inc. specializes in autologous stem cell therapies, particularly VesCell™ (ACP-01), targeting various conditions including vascular dementia, chronic limb threatening ischemia, and congestive heart failure [1][12] - The company has completed seven clinical studies involving 318 subjects and has published results in eleven peer-reviewed publications [12] Clinical Trial Details - The Phase I clinical trial protocol for ACP-01 has been submitted to an Institutional Review Board (IRB) for ethical review, with revisions made based on initial comments [9][10] - Dr. Shankle is reviewing a patient database of approximately 500 individuals diagnosed with cognitive impairment to identify up to 30 patients for the trial [10] Dr. William R. Shankle's Background - Dr. Shankle has over 35 years of medical practice, focusing on cognitive disorders and has been involved in numerous clinical programs and public education initiatives [2][3] - He is the founder of The Shankle Clinic and has held leadership roles at the University of California, Irvine, contributing to advancements in the understanding of vascular dementia [3][4] ACP-01 and Vascular Dementia - ACP-01 is designed to promote angiogenesis and microvascular repair, addressing the vascular underpinnings of vascular dementia [5][8] - The therapy has shown safety and clinical relevance in treating other conditions, with significant outcomes reported in previous studies [12]